HUE072418T2 - Metallotionein inhibitorok cukorbetegség, hepatitisz és/vagy gyulladásos májbetegség kezelésére - Google Patents
Metallotionein inhibitorok cukorbetegség, hepatitisz és/vagy gyulladásos májbetegség kezeléséreInfo
- Publication number
- HUE072418T2 HUE072418T2 HUE19703874A HUE19703874A HUE072418T2 HU E072418 T2 HUE072418 T2 HU E072418T2 HU E19703874 A HUE19703874 A HU E19703874A HU E19703874 A HUE19703874 A HU E19703874A HU E072418 T2 HUE072418 T2 HU E072418T2
- Authority
- HU
- Hungary
- Prior art keywords
- metallothionein
- hepatitis
- inhibitors
- liver disease
- treating diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618332P | 2018-01-17 | 2018-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE072418T2 true HUE072418T2 (hu) | 2025-11-28 |
Family
ID=65324621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19703874A HUE072418T2 (hu) | 2018-01-17 | 2019-01-17 | Metallotionein inhibitorok cukorbetegség, hepatitisz és/vagy gyulladásos májbetegség kezelésére |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11866488B2 (enExample) |
| EP (2) | EP3740282B1 (enExample) |
| JP (2) | JP7486423B2 (enExample) |
| KR (1) | KR20200110659A (enExample) |
| CN (2) | CN120267797A (enExample) |
| AU (2) | AU2019209491B2 (enExample) |
| BR (1) | BR112020014346A2 (enExample) |
| CA (1) | CA3088661A1 (enExample) |
| EA (1) | EA202091533A1 (enExample) |
| ES (1) | ES3033317T3 (enExample) |
| HR (1) | HRP20250727T1 (enExample) |
| HU (1) | HUE072418T2 (enExample) |
| IL (2) | IL276097B2 (enExample) |
| MX (1) | MX2020007384A (enExample) |
| PH (1) | PH12020551076A1 (enExample) |
| PL (1) | PL3740282T3 (enExample) |
| RS (1) | RS66918B1 (enExample) |
| SG (1) | SG11202006421RA (enExample) |
| SM (1) | SMT202500233T1 (enExample) |
| WO (1) | WO2019143767A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020234718A1 (en) | 2019-03-13 | 2023-05-18 | Tearsolutions, Inc. | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| AU2020315367A1 (en) | 2019-07-15 | 2022-02-03 | University Of Connecticut | Metallothionein antibodies and their use |
| CN110551726B (zh) * | 2019-09-06 | 2021-04-09 | 上海市肺科医院 | 一种结核杆菌阿拉伯半乳聚糖适配子及其应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| KR102191405B1 (ko) * | 2020-09-15 | 2020-12-16 | 주식회사 에이스바이오메드 | 간 질환 예방 또는 치료용 조성물 |
| CN115317502B (zh) * | 2021-12-21 | 2023-07-07 | 青岛市市立医院 | 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030007973A1 (en) | 2001-06-22 | 2003-01-09 | Lynes Michael A. | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody |
| WO2007012188A1 (en) | 2005-07-27 | 2007-02-01 | Qinghua Wang | GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES |
| CN102725312B (zh) * | 2009-10-20 | 2014-10-01 | 佐治亚州立大学研究基金会公司 | 用于糖尿病治疗和β细胞成像的蛋白药物 |
| EP2627638B1 (en) | 2010-10-14 | 2017-07-12 | Immunahr AB | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| CA2840282C (en) * | 2011-07-08 | 2018-11-13 | Universiteit Gent | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| US20160215042A1 (en) * | 2013-04-19 | 2016-07-28 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| TR201402685A1 (tr) | 2014-03-06 | 2015-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptinin farmasotik formulasyonları. |
| US10695406B2 (en) * | 2014-05-27 | 2020-06-30 | The University Of Queensland | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent |
| BR112017001931A2 (pt) | 2014-08-07 | 2017-11-28 | Regulus Therapeutics Inc | direcionamento de micrornas para distúrbios metabólicos |
-
2019
- 2019-01-17 EA EA202091533A patent/EA202091533A1/ru unknown
- 2019-01-17 CA CA3088661A patent/CA3088661A1/en active Pending
- 2019-01-17 ES ES19703874T patent/ES3033317T3/es active Active
- 2019-01-17 CN CN202510512846.1A patent/CN120267797A/zh active Pending
- 2019-01-17 AU AU2019209491A patent/AU2019209491B2/en active Active
- 2019-01-17 SM SM20250233T patent/SMT202500233T1/it unknown
- 2019-01-17 US US16/961,327 patent/US11866488B2/en active Active
- 2019-01-17 BR BR112020014346-4A patent/BR112020014346A2/pt unknown
- 2019-01-17 RS RS20250601A patent/RS66918B1/sr unknown
- 2019-01-17 KR KR1020207022117A patent/KR20200110659A/ko active Pending
- 2019-01-17 EP EP19703874.8A patent/EP3740282B1/en active Active
- 2019-01-17 JP JP2020537722A patent/JP7486423B2/ja active Active
- 2019-01-17 CN CN201980008316.6A patent/CN111801140B/zh active Active
- 2019-01-17 WO PCT/US2019/013934 patent/WO2019143767A1/en not_active Ceased
- 2019-01-17 IL IL276097A patent/IL276097B2/en unknown
- 2019-01-17 SG SG11202006421RA patent/SG11202006421RA/en unknown
- 2019-01-17 HU HUE19703874A patent/HUE072418T2/hu unknown
- 2019-01-17 IL IL316486A patent/IL316486A/en unknown
- 2019-01-17 MX MX2020007384A patent/MX2020007384A/es unknown
- 2019-01-17 PL PL19703874.8T patent/PL3740282T3/pl unknown
- 2019-01-17 HR HRP20250727TT patent/HRP20250727T1/hr unknown
- 2019-01-17 EP EP25158063.5A patent/EP4596042A3/en active Pending
-
2020
- 2020-07-14 PH PH12020551076A patent/PH12020551076A1/en unknown
-
2022
- 2022-08-12 AU AU2022215285A patent/AU2022215285B2/en active Active
-
2023
- 2023-07-24 US US18/357,632 patent/US20240025981A1/en active Pending
- 2023-10-27 US US18/496,279 patent/US20240067710A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002422A patent/JP2024028454A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3740282T3 (pl) | Inhibitory metalotioneiny do leczenia cukrzycy, zapalenia wątroby i/lub zapalnej choroby wątroby | |
| IL283268A (en) | Methods and devices for treating a disease with biotherapeutics | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| DK3880660T3 (da) | Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet | |
| IL285461A (en) | Processes and compounds | |
| HUE048028T2 (hu) | Acél préskeményítéshez, valamint ilyen acélból készített préskeményített alkatrész | |
| KR102223657B9 (ko) | 염증성 장질환 예방 또는 치료용 약학적 조성물 | |
| EP3784716A4 (en) | Curative | |
| SG11202012289UA (en) | Kdm1a inhibitors for the treatment of disease | |
| DK3897672T3 (da) | Hbv kombinationsbehandling | |
| IL261738A (en) | Method and composition for treating inflammatory bowel disease | |
| EP3833820C0 (en) | ENHANCED CHARGER CONTROLS | |
| DK3833746T3 (da) | Mini-gde til behandlingen af glykogenlagringssygdom iii | |
| SMT202500382T1 (it) | Composizioni per trattare e/o prevenire malattie da aggregazione proteica | |
| GB201721287D0 (en) | Treatment for inflammatory disease | |
| LT4034122T (lt) | Hiperfenilalaninemijos gydymo būdai | |
| ZA202205289B (en) | Compositions and methods for treating liver disease | |
| IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
| IL286857A (en) | Methods for the treatment of beta-thalassemia | |
| IL281140A (en) | Compounds and methods for treating fungal infections | |
| DK3319616T3 (da) | Pektinsammensætninger til at forebygge og behandle inflammatoriske sygdomme | |
| HUE053924T2 (hu) | Kompozíció cukorbetegség kezelésére | |
| SE540333C2 (sv) | Method and arrangement for metal hardening | |
| IL278984A (en) | Spinamide for the treatment of muscle deformity | |
| SMT202200418T1 (it) | Composti per prevenire e tratiare affezioni della pelle o delle mucose con componente infiammatoria |